Novel endopeptidase overcoming lysostaphin resistance
Piotr Henryk Małecki, Karolina Trochimiak, Elżbieta Jagielska, Michał Zaród, Małgorzata Korzeniowska née Wiweger, Weronika Augustyniak, Izabela Sabała · 2026
Read Novel endopeptidase overcoming lysostaphin resistance by Piotr Henryk Małecki, Karolina Trochimiak, Elżbieta Jagielska, Michał Zaród, Małgorzata Korzeniowska née Wiweger, Weronika Augustyniak, Izabela Sabała (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13490525.txt.
Description
Małecki and team discovered a bacterial enzyme that slices the cell walls of staph bacteria even when those walls carry the modification that defeats the best-known enzyme drug. Lysostaphin kills Staphylococcus aureus by cutting wall cross-bridges, but resistant strains swap in serine-containing bridges it cannot cut. Their 2026 study cloned three versions of the new enzyme, LssR, from a related staph species, purified them, and tuned their working conditions.
All three versions, full-length, mature, and the catalytic core alone, dissolved live staph cells robustly in the reported assays. Crucially, they cut the serine-containing cross-bridges that confer lysostaphin resistance, a first for this enzyme family according to the authors. Each variant had its own optimal conditions, giving formulators choices. Małecki proposes LssR as a candidate antimicrobial for the day lysostaphin resistance spreads clinically.
Catalog record
| CREATOR | Piotr Henryk Małecki, Karolina Trochimiak, Elżbieta Jagielska, Michał Zaród, Małgorzata Korzeniowska née Wiweger, Weronika Augustyniak, Izabela Sabała |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |